サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1640825

カテーテル関連尿路感染症治療市場：世界の産業分析、市場規模・シェア・成長・動向、将来予測 (2025～2032年)

Catheter Associated Urinary Tract Infections Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2025 - 2032

出版日
ページ情報
英文 216 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
カテーテル関連尿路感染症治療市場：世界の産業分析、市場規模・シェア・成長・動向、将来予測 (2025～2032年)
出版日: 2025年01月23日
発行: Persistence Market Research
ページ情報: 英文 216 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

Persistence Market Research社はこのほど、世界のカテーテル関連尿路感染症 (CAUTI) 治療市場に関する包括的なレポートを発表し、推進力、新たな動向、機会、課題など、主要な市場力学の詳細な分析を提供しました。本レポートは、市場情勢を詳細に理解し、利害関係者が十分な情報を得た上で意思決定できるよう支援します。

主要な洞察

  • カテーテル関連尿路感染症治療の市場規模 (2025年)：15億米ドル
  • 市場規模の予測 (金額ベース、2032年)：19億米ドル
  • 世界市場の成長率 (CAGR、2025～2032年)：3.70%

カテーテル関連尿路感染症治療市場：分析範囲

世界のカテーテル関連尿路感染症 (CAUTI) 治療市場は、尿道カテーテルの使用に起因する感染症の管理と根絶を目的とした治療介入に焦点を当てています。これらの感染症は、医療環境、特に留置カテーテルを使用している患者の間で蔓延している合併症です。治療の主な目的は、細菌感染と闘い、病原体の拡散を防ぎ、全身合併症のリスクを低減することです。治療の選択肢には一般的に抗菌薬が含まれるが、抗生物質耐性に対する懸念の高まりが革新的な治療法や抗菌技術の研究を後押ししています。尿道カテーテルの普及によってCAUTIの発生率が増加していることが、効果的な治療ソリューションに対する需要をさらに押し上げています。

市場成長の促進要因：

CAUTI治療市場の成長は、カテーテル関連感染を起こしやすい世界人口の高齢化によって大きく牽引されています。これと並行して、革新的な抗生物質、防腐剤、耐感染性を備えたカテーテル材料の開発など、治療方法の進歩がCAUTI管理の強化に不可欠です。これらの進歩により、特に抗生物質耐性により従来の抗生物質治療が十分でないようなケースにおいて、より的を絞った効果的な治療が可能となります。カテーテルへの抗菌性コーティングや標的ドラッグデリバリーシステムなどの最先端技術の統合は、感染予防と治療効果を向上させ、市場成長をさらに後押ししています。これらの技術革新は、既存の治療格差に対処するだけでなく、感染伝播のリスクを低減し、患者の転帰改善に貢献します。

市場の抑制要因：

有望な成長にもかかわらず、市場は大きな課題に直面しています。新薬や医療機器の厳しい承認プロセスなどの規制上のハードルは、製品のイントロダクションを遅らせ、市場の進展を阻害する可能性があります。こうした規制上の要求に対応できるリソースを持つ大手製薬企業や医療機器企業が市場を独占する可能性が高く、中小企業のビジネスチャンスを制限し、市場の多様性を低下させる可能性があります。さらに、抗生物質耐性の問題が依然としてCAUTI治療の大きな障害となっています。従来の抗生物質に対する耐性菌の増加により、治療成果を上げることがますます難しくなっており、新たな抗菌薬や代替治療アプローチの開発が必要となっています。

市場機会：

CAUTI治療市場は、特に新規治療法や技術の開発を通じて大きな成長機会をもたらします。カテーテルに抗菌性コーティングを採用することで、感染リスクを大幅に低減できる可能性が高まっています。さらに、新しい薬剤の処方や先進的なドラッグデリバリーシステムの使用は、効果的な治療に新たな道を提供します。医療プロバイダーが感染予防と管理を優先する中、医療技術の革新とともに研究開発の取り組みが拡大すると予想されます。市場はまた、医療投資の増加や感染制御技術の進歩から恩恵を受け、CAUTIの複雑性に対処し患者ケアを改善する先進治療のイントロダクションの新たな機会を創出する態勢を整えています。

当レポートで回答する主な質問

  • カテーテル関連尿路感染症治療市場の成長を促す主な要因は何か？
  • CAUTI治療市場では、どのような新しい技術や治療方法が注目を集めているか？
  • 予測期間中に最も高い市場成長が見込まれる地域はどこか？
  • カテーテル関連尿路感染症治療市場の主要企業はどこか？また、どのような戦略でその地位を維持しているのか？
  • 医療技術の進歩は、市場の競争情勢をどのように形成しているのか？

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の範囲と定義
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
    • 課題
    • 主な動向
  • ライフサイクル分析：薬剤の種類別
  • カテーテル関連尿路感染症治療市場：バリューチェーン
    • 原材料サプライヤー一覧
    • メーカー一覧
    • 販売代理店一覧
    • 流通チャネル一覧
    • 収益性分析
  • ポーターファイブフォースの分析
  • 地政学的緊張：市場への影響
  • マクロ経済要因
    • 世界のセクター別展望
    • 世界のGDP成長見通し
    • 世界の親市場概要
  • 予測要因：関連性と影響
  • 予測要因- 関連性と影響
  • 規制と技術の情勢

第3章 世界のカテーテル関連尿路感染症治療市場の展望：過去 (2019～2023年) と予測 (2025～2032年)

  • 主なハイライト
    • 市場規模の予測 (数量ベース)
    • 市場規模と前年比成長率
    • 絶対的収益機会
  • 市場規模の分析と予測 (金額 (10億米ドル)・数量ベース)
    • 過去の市場規模の分析 (2019～2023年)
    • 現在の市場規模の予測 (2025～2032年)
  • 世界のカテーテル関連尿路感染症治療市場の展望：薬剤の種類別
    • イントロダクション/主な調査結果
    • 過去の市場規模の分析：薬剤の種類別 (金額 (10億米ドル)・数量ベース、2019～2023年)
    • 現在の市場規模の予測：薬剤の種類別 (金額 (10億米ドル)・数量ベース、2025～2032年)
      • ペニシリンとその組み合わせ
      • キノロン
      • セファロスポリン
      • アミノグリコシド系抗生物質
      • スルホンアミド
      • アゾールとアムホテリシンB
      • テトラサイクリン
      • ニトロフラン
      • その他
  • 市場魅力分析：薬剤の種類別
  • 世界のカテーテル関連尿路感染症治療市場の展望：適応症の種類別
    • イントロダクション/主な調査結果
    • 過去の市場規模の分析：適応症の種類別 (金額 (10億米ドル)・数量ベース、2019～2023年)
    • 現在の市場規模の予測：適応症の種類別 (金額 (10億米ドル)・数量ベース、2025～2032年)
      • 無症候性CAUTI (細菌尿)
      • 症候性CAUTI (菌血症)
  • 市場魅力分析：適応症の種類別
  • 世界のカテーテル関連尿路感染症治療市場の展望：流通チャネル別
    • イントロダクション/主な調査結果
    • 過去の市場規模の分析：流通チャネル別 (金額 (10億米ドル)・数量ベース、2019～2023年)
    • 現在の市場規模の予測：流通チャネル別 (金額 (10億米ドル)・数量ベース、2025～2032年)
      • 病院薬局
      • 婦人科・泌尿器科クリニック
      • ドラッグストア
      • 小売薬局
      • オンラインドラッグストア
  • 市場魅力分析：流通チャネル別

第4章 世界のカテーテル関連尿路感染症治療市場の展望：地域別

  • 主なハイライト
  • 過去の市場規模の分析：地域別 (金額 (10億米ドル)・数量ベース、2019～2023年)
  • 現在の市場規模の予測：地域別 (金額 (10億米ドル)・数量ベース、2025～2032年)
    • 北米
    • 欧州
    • 東アジア
    • 南アジア・オセアニア
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場魅力分析：地域別

第5章 北米のカテーテル関連尿路感染症治療市場の展望：過去 (2019～2023年) と予測 (2025～2032年)

第6章 欧州のカテーテル関連尿路感染症治療市場の展望：過去 (2019～2023年) と予測 (2025～2032年)

第7章 東アジアのカテーテル関連尿路感染症治療市場の展望：過去 (2019～2023年) と予測 (2025～2032年)

第8章 南アジア・オセアニアのカテーテル関連尿路感染症治療市場の展望：過去 (2019～2023年) と予測 (2025～2032年)

第9章 ラテンアメリカのカテーテル関連尿路感染症治療市場の展望：過去 (2019～2023年) と予測 (2025～2032年)

第10章 中東・アフリカのカテーテル関連尿路感染症治療市場の展望：過去 (2019～2023年) と予測 (2025～2032年)

第11章 競合情勢

  • 市場シェア分析 (2025年)
  • 市場構造
    • 競合激化マップ：市場別
    • 競合：キノロン
    • 見かけの製品容量
  • 企業プロファイル (詳細：概要、財務、戦略、最近の動向)
    • Pfizer Inc.
    • Merck &Co., Inc.
    • GlaxoSmithKline (GSK)
    • AstraZeneca
    • Bayer AG
    • Johnson &Johnson
    • Novartis International AG
    • Sanofi
    • Roche Holding AG
    • Eli Lilly and Company
    • Bristol-Myers Squibb Company
    • Abbott Laboratories
    • Astellas Pharma Inc.
    • Boehringer Ingelheim
    • Daiichi Sankyo Company, Limited
    • Gilead Sciences, Inc.
    • Mylan NV
    • Teva Pharmaceutical Industries Ltd.
    • Sun Pharmaceutical Industries Ltd.

第12章 付録

  • 分析手法
  • 分析の前提条件
  • 頭字語と略語
目次
Product Code: PMRREP33711

Persistence Market Research has recently released a comprehensive report on the global Catheter Associated Urinary Tract Infections (CAUTI) Treatment Market, providing an in-depth analysis of key market dynamics, including driving forces, emerging trends, opportunities, and challenges. This report offers a detailed understanding of the market landscape, helping stakeholders make well-informed decisions.

Key Insights:

  • Catheter Associated Urinary Tract Infections Treatment Market Size (2025E): US$1.5 Bn
  • Projected Market Value (2032F): US$1.9 Bn
  • Global Market Growth Rate (CAGR 2025 to 2032): 3.70%

Catheter Associated Urinary Tract Infections Treatment Market - Report Scope:

The global catheter associated urinary tract infections (CAUTIs) treatment market focuses on therapeutic interventions designed to manage and eradicate infections that arise from the use of urinary catheters. These infections are prevalent complications in healthcare settings, particularly among patients with indwelling catheters. The primary aim of treatment is to combat bacterial infections, prevent the spread of pathogens, and reduce the risk of systemic complications. Treatment options typically include antimicrobial agents, although growing concerns about antibiotic resistance have driven research into innovative therapies and antimicrobial technologies. The increasing incidence of CAUTIs, amplified by the widespread use of urinary catheters, further propels the demand for effective treatment solutions.

Market Drivers:

The growth of the CAUTI treatment market is being significantly driven by the aging global population, which is more prone to catheter-associated infections. In parallel, advancements in treatment modalities, including the development of innovative antibiotics, antiseptics, and catheter materials with built-in infection-resistant properties, are crucial in enhancing CAUTI management. These advancements allow for more targeted and effective treatments, particularly in cases where traditional antibiotic therapies may not be sufficient due to antibiotic resistance. The integration of cutting-edge technologies, such as antibacterial coatings on catheters and targeted drug delivery systems, has improved infection prevention and treatment efficacy, further driving market growth. These innovations not only address the existing treatment gap but also reduce the risk of infection transmission, contributing to better patient outcomes.

Market Restraints:

Despite the promising growth, the market faces significant challenges. Regulatory hurdles, including the stringent approval processes for new medications and medical devices, could delay product introductions, thereby hindering market progress. Larger pharmaceutical and medical device companies, with the resources to meet these regulatory demands, are likely to dominate the market, which could limit opportunities for smaller companies and reduce market diversity. Additionally, the widespread issue of antibiotic resistance remains a major obstacle in the CAUTI treatment landscape. The increasing resistance of bacterial strains to conventional antibiotics makes it increasingly difficult to achieve successful treatment outcomes, necessitating the development of new antimicrobial agents and alternative treatment approaches.

Market Opportunities:

The CAUTI treatment market presents significant growth opportunities, particularly through the development of novel therapies and technologies. There is increasing potential in the adoption of antimicrobial coatings for catheters, which can significantly reduce the risk of infections. Furthermore, novel drug formulations and the use of advanced drug delivery systems offer new avenues for effective treatment. As healthcare providers prioritize infection prevention and management, research and development initiatives, along with innovations in medical technology, are expected to expand. The market is also poised to benefit from increased healthcare investments and advancements in infection control technologies, creating new opportunities for the introduction of advanced treatments that address the complexities of CAUTIs and improve patient care.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the catheter associated urinary tract infections treatment market?
  • What novel technologies and treatment modalities are gaining traction in the CAUTI treatment market?
  • Which regions are expected to experience the highest market growth over the forecast period?
  • Who are the key players in the catheter associated urinary tract infections treatment market, and what strategies are they using to maintain their positions?
  • How are advancements in healthcare technologies shaping the competitive landscape of the market?

Competitive Intelligence and Business Strategy:

Leading players in the global CAUTI treatment market are focusing on product innovation, clinical trials, and collaborations with research institutions to maintain a competitive edge. These companies are investing heavily in developing advanced antimicrobial technologies, such as catheter coatings and drug delivery systems, to address the growing challenges of CAUTI management. Additionally, strategic partnerships with healthcare providers and academic institutions are accelerating the development of new solutions to improve patient outcomes and reduce healthcare-associated infections. Companies are also exploring opportunities to expand their portfolios to include a broader range of treatment options that address the complexities associated with CAUTIs, ensuring they meet the diverse needs of the global healthcare market.

Key Companies Profiled:

  • Pfizer Inc.
  • Merck & Co., Inc.
  • GlaxoSmithKline (GSK)
  • AstraZeneca
  • Bayer AG
  • Johnson & Johnson
  • Novartis International AG
  • Sanofi
  • Roche Holding AG
  • Eli Lilly and Company
  • Bristol-Myers Squibb Company
  • Abbott Laboratories
  • Astellas Pharma Inc.
  • Boehringer Ingelheim
  • Daiichi Sankyo Company, Limited
  • Gilead Sciences, Inc.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sun Pharmaceutical Industries Ltd.

Catheter Associated Urinary Tract Infections Treatment Market Segmentation:

By Drug Type:

  • Penicillin & Combinations
  • Quinolones
  • Cephalosporin
  • Aminoglycoside Antibiotics
  • Sulphonamides (Sulfamethoxazole +Trimethoprim)
  • Azoles and Amphotericin B
  • Tetracycline (Doxycycline)
  • Nitrofura

By Indication Type:

  • Asymptomatic CAUTI (Bacteriuria)
  • Symptomatic CAUTI (Bacteremic)

By Distribution Channel:

  • Hospital Pharmacies
  • Gynaecology and Urology Clinics
  • Drug Stores
  • Retail Pharmacies
  • Online Drug Stores

By Region:

  • North America
  • Europe
  • East Asia
  • South Asia & Oceania
  • Latin America
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Catheter-Associated Urinary Tract Infections Treatment Market Snapshot, 2025 - 2032
  • 1.2. Market Opportunity Assessment, 2025 - 2032, US$ Bn
  • 1.3. Key Market Trends
  • 1.4. Future Market Projections
  • 1.5. Premium Market Insights
  • 1.6. Industry Developments and Key Market Events
  • 1.7. PMR Analysis and Recommendations

2. Market Overview

  • 2.1. Market Scope and Definition
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Opportunity
    • 2.2.4. Challenges
    • 2.2.5. Key Trends
  • 2.3. Drug Type Lifecycle Analysis
  • 2.4. Catheter-Associated Urinary Tract Infections Treatment Market: Value Chain
    • 2.4.1. List of Raw Material Supplier
    • 2.4.2. List of Manufacturers
    • 2.4.3. List of Distributors
    • 2.4.4. List of Distribution Channels
    • 2.4.5. Profitability Analysis
  • 2.5. Porter Five Force's Analysis
  • 2.6. Geopolitical Tensions: Market Impact
  • 2.7. Macro-Economic Factors
    • 2.7.1. Global Sectorial Outlook
    • 2.7.2. Global GDP Growth Outlook
    • 2.7.3. Global Parent Market Overview
  • 2.8. Forecast Factors - Relevance and Impact
  • 2.9. Regulatory and Technology Landscape

3. Global Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Historical (2019 - 2023) and Forecast (2025 - 2032)

  • 3.1. Key Highlights
    • 3.1.1. Market Volume (Units) Projections
    • 3.1.2. Market Size and Y-o-Y Growth
    • 3.1.3. Absolute $ Opportunity
  • 3.2. Market Size (US$ Bn ) Analysis and Forecast
    • 3.2.1. Historical Market Size Analysis, 2019 - 2023
    • 3.2.2. Current Market Size Forecast, 2025 - 2032
  • 3.3. Global Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Drug Type
    • 3.3.1. Introduction / Key Findings
    • 3.3.2. Historical Market Size (US$ Bn ) and Volume (Units) Analysis By Drug Type, 2019 - 2023
    • 3.3.3. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Drug Type, 2025 - 2032
      • 3.3.3.1. Penicillin & Combinations
      • 3.3.3.2. Quinolones
      • 3.3.3.3. Cephalosporin
      • 3.3.3.4. Aminoglycoside Antibiotics
      • 3.3.3.5. Sulphonamides
      • 3.3.3.6. Azoles and Amphotericin B
      • 3.3.3.7. Tetracycline
      • 3.3.3.8. Nitrofurans
      • 3.3.3.9. Other
  • 3.4. Market Attractiveness Analysis: Drug Type
  • 3.5. Global Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Indication Type
    • 3.5.1. Introduction / Key Findings
    • 3.5.2. Historical Market Size (US$ Bn ) and Volume (Units) Analysis By Indication Type, 2019 - 2023
    • 3.5.3. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Indication Type, 2025 - 2032
      • 3.5.3.1. Asymptomatic CAUTI (Bacteriuria)
      • 3.5.3.2. Symptomatic CAUTI (Bacteremic)
  • 3.6. Market Attractiveness Analysis: Indication Type
  • 3.7. Global Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Distribution Channel
    • 3.7.1. Introduction / Key Findings
    • 3.7.2. Historical Market Size (US$ Bn ) and Volume (Units) Analysis By Distribution Channel, 2019 - 2023
    • 3.7.3. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Distribution Channel, 2025 - 2032
      • 3.7.3.1. Hospital Pharmacies
      • 3.7.3.2. Gynaecology and Urology Clinics
      • 3.7.3.3. Drug Stores
      • 3.7.3.4. Retail Pharmacies
      • 3.7.3.5. Online Drug Stores
  • 3.8. Market Attractiveness Analysis: Distribution Channel

4. Global Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Region

  • 4.1. Key Highlights
  • 4.2. Historical Market Size (US$ Bn ) and Volume (Units) Analysis By Region, 2019 - 2023
  • 4.3. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Region, 2025 - 2032
    • 4.3.1. North America
    • 4.3.2. Europe
    • 4.3.3. East Asia
    • 4.3.4. South Asia & Pacific
    • 4.3.5. Latin America
    • 4.3.6. Middle East & Africa (MEA)
  • 4.4. Market Attractiveness Analysis: Region

5. North America Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Historical (2019 - 2023) and Forecast (2025 - 2032)

  • 5.1. Key Highlights
  • 5.2. Pricing Analysis
  • 5.3. Historical Market Size (US$ Bn ) and Volume (Units) Analysis By Market, 2019 - 2023
    • 5.3.1. By Country
    • 5.3.2. By Drug Type
    • 5.3.3. By Indication Type
    • 5.3.4. By Distribution Channel
  • 5.4. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Country, 2025 - 2032
    • 5.4.1. U.S.
    • 5.4.2. Canada
  • 5.5. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Drug Type, 2025 - 2032
    • 5.5.1. Penicillin & Combinations
    • 5.5.2. Quinolones
    • 5.5.3. Cephalosporin
    • 5.5.4. Aminoglycoside Antibiotics
    • 5.5.5. Sulphonamides
    • 5.5.6. Azoles and Amphotericin B
    • 5.5.7. Tetracycline
    • 5.5.8. Nitrofurans
    • 5.5.9. Other
  • 5.6. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Indication Type, 2025 - 2032
    • 5.6.1. Asymptomatic CAUTI (Bacteriuria)
    • 5.6.2. Symptomatic CAUTI (Bacteremic)
  • 5.7. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Distribution Channel, 2025 - 2032
    • 5.7.1. Hospital Pharmacies
    • 5.7.2. Gynaecology and Urology Clinics
    • 5.7.3. Drug Stores
    • 5.7.4. Retail Pharmacies
    • 5.7.5. Online Drug Stores
  • 5.8. Market Attractiveness Analysis

6. Europe Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Historical (2019 - 2023) and Forecast (2025 - 2032)

  • 6.1. Key Highlights
  • 6.2. Pricing Analysis
  • 6.3. Historical Market Size (US$ Bn ) and Volume (Units) Analysis By Market, 2019 - 2023
    • 6.3.1. By Country
    • 6.3.2. By Drug Type
    • 6.3.3. By Indication Type
    • 6.3.4. By Distribution Channel
  • 6.4. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Country, 2025 - 2032
    • 6.4.1. Germany
    • 6.4.2. France
    • 6.4.3. U.K.
    • 6.4.4. Italy
    • 6.4.5. Spain
    • 6.4.6. Russia
    • 6.4.7. Turkey
    • 6.4.8. Rest of Europe
  • 6.5. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Drug Type, 2025 - 2032
    • 6.5.1. Penicillin & Combinations
    • 6.5.2. Quinolones
    • 6.5.3. Cephalosporin
    • 6.5.4. Aminoglycoside Antibiotics
    • 6.5.5. Sulphonamides
    • 6.5.6. Azoles and Amphotericin B
    • 6.5.7. Tetracycline
    • 6.5.8. Nitrofurans
    • 6.5.9. Other
  • 6.6. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Indication Type, 2025 - 2032
    • 6.6.1. Asymptomatic CAUTI (Bacteriuria)
    • 6.6.2. Symptomatic CAUTI (Bacteremic)
  • 6.7. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Distribution Channel, 2025 - 2032
    • 6.7.1. Hospital Pharmacies
    • 6.7.2. Gynaecology and Urology Clinics
    • 6.7.3. Drug Stores
    • 6.7.4. Retail Pharmacies
    • 6.7.5. Online Drug Stores
  • 6.8. Market Attractiveness Analysis

7. East Asia Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Historical (2019 - 2023) and Forecast (2025 - 2032)

  • 7.1. Key Highlights
  • 7.2. Pricing Analysis
  • 7.3. Historical Market Size (US$ Bn ) and Volume (Units) Analysis By Market, 2019 - 2023
    • 7.3.1. By Country
    • 7.3.2. By Drug Type
    • 7.3.3. By Indication Type
    • 7.3.4. By Distribution Channel
  • 7.4. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Country, 2025 - 2032
    • 7.4.1. China
    • 7.4.2. Japan
    • 7.4.3. South Korea
  • 7.5. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Drug Type, 2025 - 2032
    • 7.5.1. Penicillin & Combinations
    • 7.5.2. Quinolones
    • 7.5.3. Cephalosporin
    • 7.5.4. Aminoglycoside Antibiotics
    • 7.5.5. Sulphonamides
    • 7.5.6. Azoles and Amphotericin B
    • 7.5.7. Tetracycline
    • 7.5.8. Nitrofurans
    • 7.5.9. Other
  • 7.6. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Indication Type, 2025 - 2032
    • 7.6.1. Asymptomatic CAUTI (Bacteriuria)
    • 7.6.2. Symptomatic CAUTI (Bacteremic)
  • 7.7. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Distribution Channel, 2025 - 2032
    • 7.7.1. Hospital Pharmacies
    • 7.7.2. Gynaecology and Urology Clinics
    • 7.7.3. Drug Stores
    • 7.7.4. Retail Pharmacies
    • 7.7.5. Online Drug Stores
  • 7.8. Market Attractiveness Analysis

8. South Asia & Pacific Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Historical (2019 - 2023) and Forecast (2025 - 2032)

  • 8.1. Key Highlights
  • 8.2. Pricing Analysis
  • 8.3. Historical Market Size (US$ Bn ) and Volume (Units) Analysis By Market, 2019 - 2023
    • 8.3.1. By Country
    • 8.3.2. By Drug Type
    • 8.3.3. By Indication Type
    • 8.3.4. By Distribution Channel
  • 8.4. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Country, 2025 - 2032
    • 8.4.1. India
    • 8.4.2. Southeast Asia
    • 8.4.3. ANZ
    • 8.4.4. Rest of South Asia & Pacific
  • 8.5. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Drug Type, 2025 - 2032
    • 8.5.1. Penicillin & Combinations
    • 8.5.2. Quinolones
    • 8.5.3. Cephalosporin
    • 8.5.4. Aminoglycoside Antibiotics
    • 8.5.5. Sulphonamides
    • 8.5.6. Azoles and Amphotericin B
    • 8.5.7. Tetracycline
    • 8.5.8. Nitrofurans
    • 8.5.9. Other
  • 8.6. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Indication Type, 2025 - 2032
    • 8.6.1. Asymptomatic CAUTI (Bacteriuria)
    • 8.6.2. Symptomatic CAUTI (Bacteremic)
  • 8.7. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Distribution Channel, 2025 - 2032
    • 8.7.1. Hospital Pharmacies
    • 8.7.2. Gynaecology and Urology Clinics
    • 8.7.3. Drug Stores
    • 8.7.4. Retail Pharmacies
    • 8.7.5. Online Drug Stores
  • 8.8. Market Attractiveness Analysis

9. Latin America Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Historical (2019 - 2023) and Forecast (2025 - 2032)

  • 9.1. Key Highlights
  • 9.2. Pricing Analysis
  • 9.3. Historical Market Size (US$ Bn ) and Volume (Units) Analysis By Market, 2019 - 2023
    • 9.3.1. By Country
    • 9.3.2. By Drug Type
    • 9.3.3. By Indication Type
    • 9.3.4. By Distribution Channel
  • 9.4. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Country, 2025 - 2032
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America
  • 9.5. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Drug Type, 2025 - 2032
    • 9.5.1. Penicillin & Combinations
    • 9.5.2. Quinolones
    • 9.5.3. Cephalosporin
    • 9.5.4. Aminoglycoside Antibiotics
    • 9.5.5. Sulphonamides
    • 9.5.6. Azoles and Amphotericin B
    • 9.5.7. Tetracycline
    • 9.5.8. Nitrofurans
    • 9.5.9. Other
  • 9.6. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Indication Type, 2025 - 2032
    • 9.6.1. Asymptomatic CAUTI (Bacteriuria)
    • 9.6.2. Symptomatic CAUTI (Bacteremic)
  • 9.7. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Distribution Channel, 2025 - 2032
    • 9.7.1. Hospital Pharmacies
    • 9.7.2. Gynaecology and Urology Clinics
    • 9.7.3. Drug Stores
    • 9.7.4. Retail Pharmacies
    • 9.7.5. Online Drug Stores
  • 9.8. Market Attractiveness Analysis

10. Middle East & Africa Catheter-Associated Urinary Tract Infections Treatment Market Outlook: Historical (2019 - 2023) and Forecast (2025 - 2032)

  • 10.1. Key Highlights
  • 10.2. Pricing Analysis
  • 10.3. Historical Market Size (US$ Bn ) and Volume (Units) Analysis By Market, 2019 - 2023
    • 10.3.1. By Country
    • 10.3.2. By Drug Type
    • 10.3.3. By Indication Type
    • 10.3.4. By Distribution Channel
  • 10.4. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Country, 2025 - 2032
    • 10.4.1. GCC
    • 10.4.2. Egypt
    • 10.4.3. South Africa
    • 10.4.4. Northern Africa
    • 10.4.5. Rest of Middle East & Africa
  • 10.5. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Drug Type, 2025 - 2032
    • 10.5.1. Penicillin & Combinations
    • 10.5.2. Quinolones
    • 10.5.3. Cephalosporin
    • 10.5.4. Aminoglycoside Antibiotics
    • 10.5.5. Sulphonamides
    • 10.5.6. Azoles and Amphotericin B
    • 10.5.7. Tetracycline
    • 10.5.8. Nitrofurans
    • 10.5.9. Other
  • 10.6. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Indication Type, 2025 - 2032
    • 10.6.1. Asymptomatic CAUTI (Bacteriuria)
    • 10.6.2. Symptomatic CAUTI (Bacteremic)
  • 10.7. Current Market Size (US$ Bn ) and Volume (Units) Forecast By Distribution Channel, 2025 - 2032
    • 10.7.1. Hospital Pharmacies
    • 10.7.2. Gynaecology and Urology Clinics
    • 10.7.3. Drug Stores
    • 10.7.4. Retail Pharmacies
    • 10.7.5. Online Drug Stores
  • 10.8. Market Attractiveness Analysis

11. Competition Landscape

  • 11.1. Market Share Analysis, 2025
  • 11.2. Market Structure
    • 11.2.1. Competition Intensity Mapping By Market
    • 11.2.2. Competition Quinolones
    • 11.2.3. Apparent Product Capacity
  • 11.3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
    • 11.3.1. Pfizer Inc.
      • 11.3.1.1. Overview
      • 11.3.1.2. Segments and Product
      • 11.3.1.3. Key Financials
      • 11.3.1.4. Market Developments
      • 11.3.1.5. Market Strategy
    • 11.3.2. Merck & Co., Inc.
      • 11.3.2.1. Overview
      • 11.3.2.2. Segments and Product
      • 11.3.2.3. Key Financials
      • 11.3.2.4. Market Developments
      • 11.3.2.5. Market Strategy
    • 11.3.3. GlaxoSmithKline (GSK)
      • 11.3.3.1. Overview
      • 11.3.3.2. Segments and Product
      • 11.3.3.3. Key Financials
      • 11.3.3.4. Market Developments
      • 11.3.3.5. Market Strategy
    • 11.3.4. AstraZeneca
      • 11.3.4.1. Overview
      • 11.3.4.2. Segments and Product
      • 11.3.4.3. Key Financials
      • 11.3.4.4. Market Developments
      • 11.3.4.5. Market Strategy
    • 11.3.5. Bayer AG
      • 11.3.5.1. Overview
      • 11.3.5.2. Segments and Product
      • 11.3.5.3. Key Financials
      • 11.3.5.4. Market Developments
      • 11.3.5.5. Market Strategy
    • 11.3.6. Johnson & Johnson
      • 11.3.6.1. Overview
      • 11.3.6.2. Segments and Product
      • 11.3.6.3. Key Financials
      • 11.3.6.4. Market Developments
      • 11.3.6.5. Market Strategy
    • 11.3.7. Novartis International AG
      • 11.3.7.1. Overview
      • 11.3.7.2. Segments and Product
      • 11.3.7.3. Key Financials
      • 11.3.7.4. Market Developments
      • 11.3.7.5. Market Strategy
    • 11.3.8. Sanofi
      • 11.3.8.1. Overview
      • 11.3.8.2. Segments and Product
      • 11.3.8.3. Key Financials
      • 11.3.8.4. Market Developments
      • 11.3.8.5. Market Strategy
    • 11.3.9. Roche Holding AG
      • 11.3.9.1. Overview
      • 11.3.9.2. Segments and Product
      • 11.3.9.3. Key Financials
      • 11.3.9.4. Market Developments
      • 11.3.9.5. Market Strategy
    • 11.3.10. Eli Lilly and Company
      • 11.3.10.1. Overview
      • 11.3.10.2. Segments and Product
      • 11.3.10.3. Key Financials
      • 11.3.10.4. Market Developments
      • 11.3.10.5. Market Strategy
    • 11.3.11. Bristol-Myers Squibb Company
      • 11.3.11.1. Overview
      • 11.3.11.2. Segments and Product
      • 11.3.11.3. Key Financials
      • 11.3.11.4. Market Developments
      • 11.3.11.5. Market Strategy
    • 11.3.12. Abbott Laboratories
      • 11.3.12.1. Overview
      • 11.3.12.2. Segments and Product
      • 11.3.12.3. Key Financials
      • 11.3.12.4. Market Developments
      • 11.3.12.5. Market Strategy
    • 11.3.13. Astellas Pharma Inc.
      • 11.3.13.1. Overview
      • 11.3.13.2. Segments and Product
      • 11.3.13.3. Key Financials
      • 11.3.13.4. Market Developments
      • 11.3.13.5. Market Strategy
    • 11.3.14. Boehringer Ingelheim
      • 11.3.14.1. Overview
      • 11.3.14.2. Segments and Product
      • 11.3.14.3. Key Financials
      • 11.3.14.4. Market Developments
      • 11.3.14.5. Market Strategy
    • 11.3.15. Daiichi Sankyo Company, Limited
      • 11.3.15.1. Overview
      • 11.3.15.2. Segments and Product
      • 11.3.15.3. Key Financials
      • 11.3.15.4. Market Developments
      • 11.3.15.5. Market Strategy
    • 11.3.16. Gilead Sciences, Inc.
      • 11.3.16.1. Overview
      • 11.3.16.2. Segments and Product
      • 11.3.16.3. Key Financials
      • 11.3.16.4. Market Developments
      • 11.3.16.5. Market Strategy
    • 11.3.17. Mylan N.V.
      • 11.3.17.1. Overview
      • 11.3.17.2. Segments and Product
      • 11.3.17.3. Key Financials
      • 11.3.17.4. Market Developments
      • 11.3.17.5. Market Strategy
    • 11.3.18. Teva Pharmaceutical Industries Ltd.
      • 11.3.18.1. Overview
      • 11.3.18.2. Segments and Product
      • 11.3.18.3. Key Financials
      • 11.3.18.4. Market Developments
      • 11.3.18.5. Market Strategy
    • 11.3.19. Sun Pharmaceutical Industries Ltd.
      • 11.3.19.1. Overview
      • 11.3.19.2. Segments and Product
      • 11.3.19.3. Key Financials
      • 11.3.19.4. Market Developments
      • 11.3.19.5. Market Strategy

12. Appendix

  • 12.1. Research Methodology
  • 12.2. Research Assumptions
  • 12.3. Acronyms and Abbreviations